Medrx Co

Medrx Co R&D per Employee

The R&D Spending per Employee of Medrx Co (4586.T) as of Nov 19, 2026 is 38.13 M JPY. In the previous year, R&D Spending per Employee was 36.81 M JPY — a change of 3.58% (higher).

R&D per Employee

38.13 MJPY

YoY

3.58%

Last updated:

R&D Spending per Employee of Medrx Co is 2025 38.13 M JPY. R&D Spending per Employee of Medrx Co was 2024 36.81 M JPY. It decreases by 3.58% higher compared to the previous year.

The Medrx Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
42.89 M JPY
Jan 1, 2019
67.04 M JPY
Jan 1, 2020
41.58 M JPY
Jan 1, 2021
33.51 M JPY
Jan 1, 2022
39.90 M JPY
Jan 1, 2023
31.55 M JPY
Jan 1, 2024
36.81 M JPY
Jan 1, 2025
38.13 M JPY
The Medrx Co R&D per Employee history
YEARR&D per EmployeeYoY
38.13 MJPY+3.58%
36.81 MJPY+16.67%
31.55 MJPY-20.92%
39.90 MJPY+19.08%
33.51 MJPY-19.41%
41.58 MJPY-37.98%
67.04 MJPY+56.31%
42.89 MJPY+13.41%
37.82 MJPY-18.43%
46.36 MJPY+58.41%
29.27 MJPY-3.88%
30.45 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

R&D Spending per Employee of Medrx Co is 38.13 M JPY in 2025.

R&D Spending per Employee of Medrx Co changed from 36.81 M JPY to 38.13 M JPY, representing a 3.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Medrx Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Medrx Co

All Key Metrics — Medrx Co